Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2 (POCT-DOAC 2)

University Hospital Tuebingen

Status

Completed

Conditions

Anticoagulation With Direct Oral Anticoagulants

Study type

Observational

Funder types

Other

Identifiers

NCT02371070

.1 259/2013BO1

Details and patient eligibility

About

The investigators study aims to test the correlation between the Hemochron Signature point-of-care testing (POCT) device (ITC, USA) and low plasma levels of all three currently approved direct oral anticoagulants (DOAC; rivaroxaban, apixaban and dabigatran) and to determine the diagnostic accuracy of POCT to rule out or detect relevant levels of DOAC in real-life stroke patients.

Enrollment

60 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Stroke patients, who were newly started on oral anticoagulation with rivaroxaban, apixaban or dabigatran for secondary prevention of thromboembolic events
Age ≥ 18 years

Exclusion criteria

Vitamin K antagonists or direct oral anticoagulants ≤ 14 days prior to study participation
Low-molecular weight heparin ≤ 24 hours
Unfractionated heparin ≤ 12 hours
Abnormal coagulation values at baseline (Quick < 70% or activated thromboplastin time (aPTT) > 40sec.)
History of coagulopathy